Abstract
Introduction
In vivo imaging enables researchers to view biological processes at the molecular level. In vivo molecular imaging techniques have important implications for drug discovery and development because they aid in validating drug targets and in studying the biodistribution, target binding, clinical effects, and toxicity of drug candidates.
Get the Answers You Need to Shape Your Strategy
The development of in vivo molecular imaging techniques has important implications for drug discovery and development. How will pharmaceutical companies use this valuable information to accelerate their drug development process? Which imaging companies are the major players in this fi eld?
The FDA has introduced a new exploratory investigational new drug (eIND) mechanism that encourages companies to use imaging techniques during early-stage microdosing studies. How can pharmaceutical companies best capitalize on this new mechanism? Which imaging technologies are likely to see increased use as the result of eIND? The high cost of in vivo molecular imaging poses a signifi cant barrier to its widespread adoption. Will pharmaceutical and biotech companies decide to invest in these technologies despite the cost or will they seek other options?
The development of combined PET-MRI instrumentation will be a major breakthrough. How close to market are these powerful new tools? What new benefi ts will they offer?
Scope
- Factors fueling the molecular imaging market: trend toward systems biology and personalized medicine, FDA Critical Path initiative, and eINDs.
- In vivo imaging technologies: computed tomography (CT), positron emission tomography (PET), single photon emission CT (SPECT), magnetic resonance imaging (MRI), functional MRI, optical
- imaging, and the use of model organisms.
- Imaging initiatives: a review of important new imaging initiatives related to biomarkers, Alzheimer's disease, lung cancer, and osteoarthritis.
- Applications of imaging to key therapeutic areas: a discussion of applications in cancer, the brain, and central nervous system disorders.
- Corporate profiles: features on key players in this growing fi eld.
- Outlook for molecular imaging: our take on how the role of molecular imaging in drug development will evolve over the next several years.
Mentioned in This Spectrum Report-Companies
- Affi body
- Agfa HealthCare
- Alerion Biomedical
- Amersham
- ART Advanced Research Technologies
- Biospace Med
- Bristol-Myers Squibb
- Bruker Biospin
- Caliper Life Sciences
- Cardinal Health
- CTI Molecular Imaging
- Eastman Kodak Health Group
- Eisai
- Elan
- Epix Pharmaceuticals
- Fujifi lm Medical Systems USA
- Gamma Medica-Ideas
- GE Healthcare
- General Electric
- GlaxoSmithKline
- Hamamatsu
- iCAD
- Insight NeuroImaging Systems
- Invitrogen
- Ixico
- Johnson & Johnson
- Kereos
- Kodak
- Li-Cor Biosystems
- Eli Lilly
- MDS Nordion
- Merck
- MIR Preclinical Services
- Molecular Insight Pharmaceuticals
- Novartis
- Pfi zer
- Philips Medical Systems
- Regional Nuclear Pharmaceuticals
- Riverain
- Roche
- SA Instruments
- Siemens Medical Solutions
- Stentor
- Varian Instruments
- VisEn Medical
- Wyeth
- Xenogen
- Zecotek
- Zygogen
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Factors Driving the Development and Adoption of In Vivo Imaging
- Trend Toward Systems Biology
- Trend Toward Personalized Medicine
- FDA Critical Path Initiative
- Exploratory IND and Microdosing Studies
- In Vivo Imaging Technologies
- Computed Tomography
- Positron Emission Tomography
- Single Photon Emission Computed Tomography
- Magnetic Resonance Imaging
- Functional Magnetic Resonance Imaging
- Optical Imaging
- Imaging Initiatives
- Biomarker Consortium
- Alzheimer's Disease Neuroimaging Initiative
- Lung Cancer Initiative
- Osteoarthritis Initiative
- In Vivo Imaging with Model Organisms
- Biophotonic Mice
- Zebrafish
- Applications of Imaging to Cancer
- Applications of Imaging to the Brain and CNS Disorders
- Corporate Profiles
- Gamma Medica-Ideas
- GE Healthcare
- Varian
- VisEn Medical
- Xenogen
- Zecotek Medical Systems
- Zygogen
- Outlook for Molecular Imaging
Tables
- 1. In Vivo Molecular Imaging Techniques: Strengths, Weaknesses, and Opportunities
- 2. Applications of Select In Vivo Imaging Approaches
- 3. Select Companies Active in In Vivo Imaging
- 4. Select Alliances and Acquisitions in the In Vivo Imaging Field
Figures
- 1. Growth in Publications on In Vivo Imaging Research
- 2. Trend Toward Quantitative In Vivo Imaging Models
- 3. FDG Uptake in a Xenograft Tumor in Mouse
